scholarly journals Review on molnupiravir as a promising oral drug for the treatment of COVID-19

Author(s):  
Elham Zarenezhad ◽  
Mahrokh Marzi
Keyword(s):  
1983 ◽  
Vol 50 (04) ◽  
pp. 852-856 ◽  
Author(s):  
P Gresele ◽  
C Zoja ◽  
H Deckmyn ◽  
J Arnout ◽  
J Vermylen ◽  
...  

SummaryDipyridamole possesses antithrombotic properties in the animal and in man but it does not inhibit platelet aggregation in plasma. We evaluated the effect of dipyridamole ex vivo and in vitro on platelet aggregation induced by collagen and adenosine- 5’-diphosphate (ADP) in human whole blood with an impedance aggregometer. Two hundred mg dipyridamole induced a significant inhibition of both ADP- and collagen-induced aggregation in human blood samples taken 2 hr after oral drug intake. Administration of the drug for four days, 400 mg/day, further increased the antiplatelet effect. A significant negative correlation was found between collagen-induced platelet aggregation in whole blood and dipyridamole levels in plasma (p <0.001). A statistically significant inhibition of both collagen (p <0.0025) and ADP-induced (p <0.005) platelet aggregation was also obtained by incubating whole blood in vitro for 2 min at 37° C with dipyridamole (3.9 μM). No such effects were seen in platelet-rich plasma, even after enrichment with leukocytes. Low-dose adenosine enhanced in vitro inhibition in whole blood.Our results demonstrate that dipyridamole impedes platelet aggregation in whole blood by an interaction with red blood cells, probably involving adenosine.


1959 ◽  
Vol XXXII (IV) ◽  
pp. 491-496 ◽  
Author(s):  
Robert S. Walker ◽  
Adam L. Linton

ABSTRACT A brief comparison of phenethyl-biguanide (D. B. I.) with other oral hypoglycaemic drugs is made. A series of 31 juvenile diabetics treated with D. B. I. is described, and the reasons for partial success or failure are considered. The advantages and dangers of the drug are discussed. It is concluded that the unique action of this drug may give it a place in the treatment of juvenile diabetes.


Author(s):  
Kathpalia Harsha ◽  
Das Sukanya

Ion Exchange Resins (IER) are insoluble polymers having styrene divinylbenzene copolymer backbone that contain acidic or basic functional groups and have the ability to exchange counter ions with the surrounding aqueous solutions. From the past many years they have been widely used for purification and softening of water and in chromatographic columns, however recently their use in pharmaceutical industry has gained considerable importance. Due to the physical stability and inert nature of the resins, they can be used as a versatile vehicle to design several modified release dosage forms The ionizable drug is complexed with the resin owing to the property of ion exchange. This resin complex dissociatesin vivo to release the drug. Based on the dissociation strength of the drug from the drug resin complex, various release patterns can be achieved. Many formulation glitches can be circumvented using ion exchange resins such as bitter taste and deliquescence. These resins also aid in enhancing disintegrationand stability of formulation. This review focuses on different types of ion exchange resins, their preparation methods, chemistry, properties, incompatibilities and their application in various oral drug delivery systems as well as highlighting their use as therapeutic agents.


2015 ◽  
Vol 21 (15) ◽  
pp. 2021-2036 ◽  
Author(s):  
Himani Kapahi ◽  
Nikhat Khan ◽  
Ankur Bhardwaj ◽  
Neeraj Mishra

Sign in / Sign up

Export Citation Format

Share Document